Logo

Suggestions

  • Cancer Disparities
  • Opinion
  • Conferences
  • News
  • Patient Corner
  • About
    • Contact
    • Article Submission
  • Top Headlines
    • Cancer Types
      • Breast Cancer
      • Cervical Cancer
      • GI Malignancies
      • Melanoma & Skin Cancer
      • GU Malignancies
      • Gynecologic Oncology
      • Hematologic Malignancies
      • Lung Cancer
  • Expert Opinion
  • Video News
  • New Approvals
  • Cancer Disparities
  • Patient Corner
  • Subscribe

Logo

ctDNA as prognostic marker

April 10, 2023
Breast Cancer/Opinion

Risk Factors for Relapse Among Breast Cancer Patients with Pathological Complete Response (pCR) Post Neoadjuvant Treatment

By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center   Attainment of pathological complete response (pCR) of breast cancer is associated with improved long-term outcomes (event-free survival and overall survival) compared to

Breast Cancer/Opinion

Risk Factors for Relapse Among Breast Cancer Patients with Pathological Complete Response (pCR) Post Neoadjuvant Treatment

By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center   Attainment of pathological complete response (pCR) of breast cancer is associated with improved long-term outcomes (event-free survival and overall survival) compared to

More
by Staff Writer - The Cancer News
April 10, 2023

your advertisement here

you may also like...

  • FDA_Approved
    FDA Approves Luspatercept-aamt for Anemia in Patients with Myelodysplastic Syndromes
  • hodgkin-lymphoma
    KEYNOTE-087: Pembrolizumab Monotherapy for Relapsed/Refractory Classical Hodgkin lymphoma
  • Overview of KEYNOTE-671 & NADIM II
  • Expert Opinion: Children’s Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse
  • FDA_Approved
    FDA Approves HEPZATO KIT for Uveal Melanoma with Unresectable Hepatic Metastases

All Categories

  • Awareness
  • Breast Cancer
  • Cancer Disparities
  • Cancer Research
  • Conference 2023
  • Conference Coverage
  • Conferences
  • Events
  • GI Malignancies
  • GU Malignancies
  • Hematologic Malignancies
  • Journal
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Nepal Cancer Center
  • New Approvals
  • New Drug Applications
  • News
  • Opinion
  • Patient Corner
  • Spotlights
  • Uncategorized
  • Updates
  • Video News
  • Volunteer Spotlight

Search By Keyword

ASCO ASCO23 award Binaytara foundation breast cancer BTF cancer cancer care cancer disparities cancer research cancer survival cancer treatment Cellular therapy CME conference Conferences continuing education Dr. Binay Shah Dr Anish Shah Dr Shipra Gandhi Expert Opinion faculty highlight FDA FDA Approval FDA approved head & neck cancer surgery in Nepal healthcare equity hematological malignancies hematologic malignancies leukemia Lung cancer lymphoma multiple myeloma Nepal cancer care oncology CME SCHD video news Volunteer

We Transform Cancer Care

Dissect complex information on cancer and disseminate knowledge to healthcare professionals, patients, and caregivers. We want to improve patient outcomes.
Cover the latest research to promote precision oncology and patient-centered care.
Questions? Contact us -
[email protected]

Social Media

Advertisement


Footer Logo
  • Facebook
  • Twitter
  • LinkedIn

© 2023 - All Rights Reserved. Binaytara Foundation

  • About
  • Submit an Article
  • Subscribe for updates
  • Editorial Board
  • Privacy Policy
  • Contact
  • Home
  • Top Headlines
    • Awareness
    • Video News
    • Cancer Types
      • Breast Cancer
      • Cervical Cancer
      • Melanoma & Skin Cancer
      • GI Malignancies
      • Lung Cancer
      • Hematologic Malignancies
      • Gynecologic Oncology
      • GU Malignancies
  • New in Cancer Care
  • Conferences
    • Hemotology & Oncology Conference Calendar
    • Conference Calendar
    • Conference Coverage
  • New Approvals
  • Contact us
  • Submit an article